Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|14|7|671-683

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.7, 2014-09, pp. : 671-683

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 289-299

Bentham Science Publishers

Access to resources Recommend Favorite

Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents

By  

Current Pharmaceutical Design, Vol. 11, Iss. 9, 2005-04 ,pp. : 1131-1138

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 2, 2012-02 ,pp. : 120-126

Bentham Science Publishers

Access to resources Recommend Favorite

A Screening Method for Potential Anti-pancreatic Cancer Candidate Compounds Based on Hsp90-Cdc37 Interaction Model in vitro

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 1, 2015-01 ,pp. : 66-71

Bentham Science Publishers

Access to resources Recommend Favorite

Hyperglycemia Regulates TXNIP/TRX/ROS Axis via p38 MAPK and ERK Pathways in Pancreatic Cancer

By  

Current Cancer Drug Targets, Vol. 14, Iss. 4, 2014-05 ,pp. : 348-356

Bentham Science Publishers

Access to resources Recommend Favorite